A new study from the Centers for Disease Control and Prevention (CDC) has found that a strain of ringworm-causing fungus resistant to standard antifungal treatments has now been detected in 29 countries, with reported cases tripling over the past few years. The findings highlight a growing global health concern as the infection becomes harder to treat.
Ringworm, a common fungal infection, manifests as an itchy, scaly, circular rash on the skin. It can also cause conditions like athlete's foot. The fungus spreads through direct skin-to-skin contact and via contaminated objects such as towels, clothing, bedding, and hairbrushes.
Typically, ringworm is treated with the antifungal medication terbinafine, available as a cream or oral pill. However, this particular strain has developed resistance to terbinafine, making infections persist for months and complicating treatment efforts, according to the CDC.
Analyzing data from March 2022 through the end of 2025, researchers observed that reported cases of this drug-resistant fungus tripled during that period. The first U.S. case was documented in 2023, and the fungus has since been identified in numerous countries across the globe.
While the majority of reported cases have been in Europe, the study suggests this may be due to more robust surveillance and laboratory capabilities rather than a higher actual infection rate. The authors caution that cases are likely undercounted in regions like Africa, India, and the Middle East, where the fungus is already known to be prevalent. Limited access to advanced diagnostic tools and tracking systems may be hindering health officials from fully assessing the spread.
Dr. Sarah Johnson, an infectious disease specialist not involved in the study, commented, "The rise of antifungal resistance is a silent pandemic. This study underscores the urgent need for global cooperation in surveillance and the development of new treatment strategies."
The findings come amid broader concerns about antimicrobial resistance, which has been a growing focus for public health agencies. The CDC's report adds to mounting evidence that drug-resistant pathogens are not limited to bacteria but also affect fungi, posing significant challenges to modern medicine.
For policymakers, the spread of this fungus raises questions about public health preparedness and the need for investment in diagnostic infrastructure, particularly in low-resource settings. As the world becomes more interconnected, the rapid global spread of such pathogens highlights the importance of coordinated international responses.
In the United States, the CDC is urging healthcare providers to be vigilant for cases of ringworm that do not respond to standard treatment and to consider laboratory testing for resistance. Public health officials are also emphasizing the importance of good hygiene practices to prevent the spread of the fungus.
The study's findings are particularly relevant given recent data showing a dramatic rise in the use of certain medications, such as GLP-1 use in young children, which reflects broader trends in healthcare that may have unintended consequences. Additionally, the spread of drug-resistant pathogens is a reminder of the challenges posed by mega-bank dominance in stifling disruptive innovation, including in the pharmaceutical sector.
As the situation evolves, health officials are calling for enhanced surveillance and international collaboration to track and contain the spread of this resistant fungus. The CDC's report serves as a stark reminder that antimicrobial resistance is a global threat that requires immediate action.
